Clinical trial · Observational
Interleukin 4 and Interferon Gamma Predictors of Human Papillomavirus Immunotherapy in Warts
IL-4 and IFN-γ As Immunologic Predictors of Response to HPV Immunotherapy in Warts
NCT05100043CI-TRIAL-00086209completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In the present study the investigators assessed the invitro role of IL-4 and IFN-γ in predicting the response to bivalent HPV vaccine after whole blood stimulation
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Wart, Genital | Condyloma Acuminatum | ALIAS | 0.90 |
| Warts Hand | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| IL-4 and IFN-γ measurements | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Cases
- description
- Patients having multiple recurrent and recalcitrant cutaneous and genital warts
- interventionNames
- Biological: IL-4 and IFN-γ measurements
- label
- Controls
- description
- Healthy volunteers matched for age and sex
- interventionNames
- Biological: IL-4 and IFN-γ measurements
Primary outcomes (1)
- measure
- Change of IFN-γ and IL-4 levels
- timeFrame
- 48 hours
- description
- Quantitative measurement of IFN-γ and IL-4 in culture supernatants
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 36 Months
Show eligibility criteria text
Inclusion Criteria: * Patients with recurrent and recalcitrant cutaneous and anogenital warts. Exclusion Criteria: * History of allergy to the HPV vaccine * Active viral, fungal, or bacterial infections * Immunosuppressive diseases or drugs. * Autoimmune diseases, or other systemic diseases, e.g., hepatic, or renal disorders, diabetes, meningitis or convulsions * Skin allergies * Pregnancy and lactation * Earlier wart treatment at least one month before enrollment.
References
Publications (0)
Data not yet available
No reference posted for this study.